Genprex, Inc. (GNPX)
1.89
-0.09
(-4.55%)
USD |
NASDAQ |
Oct 23, 11:10
Genprex EPS Diluted (Quarterly) : -9.399 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.399 |
| March 31, 2026 | -14.12 |
| December 31, 2025 | -25.33 |
| September 30, 2025 | -109.90 |
| June 30, 2025 | -186.36 |
| March 31, 2025 | -0.2597 |
| December 31, 2024 | -466.68 |
| September 30, 2024 | -1.233 |
| June 30, 2024 | -3.005 |
| March 31, 2024 | -4245.71 |
| December 31, 2023 | -3.990 |
| September 30, 2023 | -5.362 |
| June 30, 2023 | -6.141 |
| March 31, 2023 | -7.441 |
| December 31, 2022 | -5.634 |
| September 30, 2022 | -5632.44 |
| June 30, 2022 | -5295.84 |
| March 31, 2022 | -4879.60 |
| December 31, 2021 | -5221.92 |
| September 30, 2021 | -2.888 |
| Date | Value |
|---|---|
| June 30, 2021 | -3.366 |
| March 31, 2021 | -5.700 |
| December 31, 2020 | -4.850 |
| September 30, 2020 | -2.842 |
| June 30, 2020 | -4.948 |
| March 31, 2020 | -7.965 |
| December 31, 2019 | -5.488 |
| September 30, 2019 | -6.002 |
| June 30, 2019 | -9.461 |
| March 31, 2019 | -5.631 |
| December 31, 2018 | -9.094 |
| September 30, 2018 | -5.958 |
| June 30, 2018 | -17.95 |
| March 31, 2018 | -2.365 |
| December 31, 2017 | -2495.24 |
| September 30, 2017 | -2676.52 |
| June 30, 2017 | -4421.12 |
| March 31, 2017 | -2.640 |
| December 31, 2016 | -3739.56 |
| September 30, 2016 | -2694.56 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.447M |
| Total Expenses (Quarterly) | 4.447M |
| Enterprise Value | -14.15M |
| Earnings Yield | -8.40K% |
| Normalized Earnings Yield | -8399.88 |